基于血的BioID优化识别了等离子素作为ADAMTS13的配体
Hasam Madarati1, Veronica DeYoung1, Kanwal Singh1
1Department of Medicine, Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada.
Scientific reports
|April 20, 2024
概括
等离子素与ADAMTS13结合,揭示了这种蛋白酶的新调节机制. 使用血BioID识别的这种相互作用表明,等离子体降解ADAMTS13,影响其在心血管系统中的活性.
科学领域:
- 蛋白质组学是指蛋白质组学.
- 生物化学 生物化学
- 心血管生物学 心血管生物学
背景情况:
- ADAMTS13调节了·维勒布兰德因子 (VWF) 的多重长度和血小板结合.
- ADAMTS13被分泌为活性蛋白酶,但其调节仍然不清楚.
- 控制ADAMTS13蛋白酶活性的机制基本上是未知的.
研究的目的:
- 使用优化的BioID方法在血中识别ADAMTS13的配体.
- 阐明ADAMTS13蛋白酶活性的新型调节机制.
- 为了研究ADAMTS13和plasminogen之间的相互作用.
主要方法:
- 对血样本的BioID (靠近依赖生物化) 的优化.
- 使用ADAMTS13-birA*融合蛋白进行无偏的蛋白质组学选.
- 与各种等离子体变异和apo(a) 的亲和结合试验.
主要成果:
- 血生物识别仪 (Plasma BioID) 确定了VWF和等离子原作为高亲和度的ADAMTS13配体.
- 特定的等离子体变体 (Glu-, Lys-, mini-) 和apo(a) 结合了ADAMTS13的C端.
- 血原结合被胺酸抑制,这也保护了ADAMTS13免受等离子体降解.
结论:
- 血原是血中ADAMTS13的关键配体,与其C端结合.
- 等离子体以依赖素的方式蛋白质分解ADAMTS13,这表明一种调节途径.
- 优化的血BioID是研究心血管系统中蛋白酶调节的宝贵工具.
相关概念视频
01:16Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689